Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

Gaudet, D, Méthot, J, Déry, S, Brisson, D, Essiembre, C, Tremblay, G, Tremblay, K, de Wal, J +4 more·2013·Gene Therapy
DOI 10.1038/gt.2012.43

Cited by (404)

Items 401–404 of 404

  1. Aav Capsid Glycoengineering: Effects of Glycan Type, Density and Conjugation Site on Vector Stability, Delivery and Gene Transduction
    Sergio Milagros, Damián Pérez‐Martínez, Samuel Salazar-Diaz, Pablo Ramírez-Ruiz de Erenchun, Marina Nicolao, Beatriz Carte, Míriam Méndez, Begoña Echevarria, Niels Reichardt, Rafael Aldabe · 2026 · Research Square
  2. Development of a Recombinant Adeno-Associated Virus Vector for Human T Lymphocyte- and Natural Killer Cell-Targeted Gene Therapy
    Hendrik Jahnz, Martin V. Hamann, H.O. Kim, Yaping Sun, Natalia A. Salazar-Quiroz, Li Zhu, Sabrina M. Leddy, Umm E Swaiba, Carola Schneider, Daniel Foth et al. · 2026 · Human Gene Therapy
  3. Impact of Extraction Recovery and Matrix Effect on qPCR-based Biodistribution Analysis in Gene Therapy: Strategies for Mitigation
    Ting Jiang, Zhaomeng Feng, Long Yuan · 2026 · The AAPS Journal
  4. Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
    Shanshan Qi, Weiwei Chen, Kunhao Chen, Song Yang, Sibo Wang, Tongtian Ni, Dan Xu, Enqiang Mao, Erzhen Chen, Ying Chen · 2026 · MedComm